AbbVie Tumbles After New Schizophrenia Drug Fails in Two Trials
3 days ago · AbbVie Inc. shares sank in early trading after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of ...
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
3 days ago · AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an ...
AbbVie’s disappointing schizophrenia drug trial bodes well for …
2 days ago · AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie ABBV said that its Phase 2 trial ...
AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia …
3 days ago · AbbVie schizophrenia drug candidate emraclidine failed to beat a placebo in two Phase 2 clinical trials. The drug, once projected to compete with Bristol Myers Squibb’s Cobenfy, is from AbbVie ...
Schizophrenia drug AbbVie picked up in $9 billion acquisition
3 days ago · Nov. 11, 2024. National Biotech Reporter. AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got ...
AbbVie's closely watched schizophrenia drug fails two studies, …
3 days ago · AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening rival Bristol Myers Squibb's lead in the market ...
AbbVie shares tumble after schizophrenia drug disappoints
3 days ago · Shares in AbbVie tumbled after the drugmaker revealed that an experimental treatment for schizophrenia, the main drug purchased as part of an $8.7bn acquisition last year, failed to meet its goals ...
AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint
3 days ago · Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of Phase 2 clinical trials. AbbVie said the trials did not show a ...
AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia ...
3 days ago · By Colin Kellaher. AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical ...
AbbVie Shares Fall Premarket After Schizophrenia Drug
3 days ago · AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares down more than 10% ...
- Some results have been removed